SSTR5 and Insulin resistance: To evaluate the therapeutic potential of SSTR5 antagonism for diabetic phenotypes, including insulin resistance, compound‐1 was orally administered to KK‐Ay mice at 1, 3, and 10 mg/kg once daily for 2 weeks.